TABLE 3.
Mode of administration and model | Immune functiona | Reference(s) |
---|---|---|
In vivo | ||
Humans | ↓Lymphoproliferation | 154 |
↓Antimicrobial activity | 14 | |
↓Cytokine production | 14 | |
Mice | ↓↑Serum Ig levels | 155 |
↓Cellular immunity | 112, 163, 214 | |
↓Antimicrobial activity | 8, 34, 147, 222 | |
↓Humoral immunity | 10, 102, 198 | |
↑Apoptosis | 140 | |
↓↑Cell signaling | 50, 241 | |
In vitro | ||
Humans | ↓Lymphocyte proliferation | 153, 221 |
↓NK cell activity | 219, 220 | |
↓Neutrophil antifungal activity | 55 | |
↑↓Cytokine production | 223, 255 | |
Mice | ↓Lymphocyte proliferation | 113, 140, 181, 182 |
↓NK cell activity | 104, 110, 133 | |
↓Antibody formation | 9, 107 | |
↓↑IL-2 system receptors | 46, 79, 270, 271 | |
↓↑Cytokine production | 14, 108, 162 | |
↑Apoptosis | 140, 269 | |
↓↑Cell signaling | 46, 62, 79 |
↑, increase; ↓, decrease; ↑↓, both increase and decrease.